Table 3.

Univariable and multivariable logistic regression for overall response.

Variable	Univariable OR (95% CI)	p value	Multivariable OR (95% CI)	p value
Age (years)	0.99 (0.97–1.02)	0.459	0.99 (0.97–1.02)	0.534
Male	0.95 (0.45–1.97)	0.883	0.88 (0.41–1.85)	0.730
Geographic region
Europe versus USA	0.63 (0.26–1.53)	0.306	0.53 (0.20–1.44)	0.213
Asia versus USA	1.28 (0.66–2.48)	0.462	1.16 (0.58–2.35)	0.676
Immunotherapy treatment
PD-1/CTLA-4 versus PD-1	1.90 (0.70–5.17)	0.209	−	−
PD-1/TKI versus PD-1	0.53 (0.12–2.36)	0.403	−	−
Second line or later	0.83 (0.45–1.51)	0.537	−	−
Cirrhosis	1.74 (0.83–3.67)	0.142	−	−
Liver disease
HCV versus HBV	0.94 (0.46–1.9)	0.852	−	−
HBV/HCV versus HBV	0.77 (0.08–6.99)	0.812	−	−
Non-viral versus HBV	0.56 (0.25–1.25)	0.159	−	−
ECOG ⩾ 1	1.08 (0.59–1.97)	0.799	−	−
BCLC C/D	0.83 (0.43–1.59)	0.567	−	−
Child–Pugh B/C	1.33 (0.70–2.51)	0.383	−	−
Portal venous thrombosis	1.04 (0.55–1.95)	0.905	−	−
Extrahepatic metastasis	0.85 (0.47–1.55)	0.602	−	−
⩾3 intrahepatic nodules	0.66 (0.36–1.22)	0.185	−	−
Maximum diameter of largest lesion (cm)	1.00 (0.99–1.01)	0.994	−	−
Alpha-fetoprotein >400 ng/ml	0.95 (0.51–1.74)	0.858	−	−
Baseline antacid exposure	1.06 (0.57–1.98)	0.847	1.32 (0.66–2.65)	0.429
Baseline PPI exposure	1.15 (0.60–2.18)	0.676	−	−
Baseline H2RA exposure	1.10 (0.36–3.42)	0.865	−	−
Baseline antibiotic exposure	0.67 (0.25–1.82)	0.435	0.60 (0.20–1.74)	0.343

BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ECOG, Eastern Cooperative Oncology Group; H2RA, histamine-2-receptor antagonist; HBV, hepatitis B virus; HCV, hepatitis C virus; OR, odds ratio; PD-1, programmed cell death protein 1; PPI, proton pump inhibitor; TKI, tyrosine kinase inhibitor.